一项中国人群的真实世界队列研究揭示年龄不是HR+/HER2-转移性乳腺癌患者的预后因素。 乳腺癌的发病高峰年龄一般出现在50岁以后,既往有研究报道年轻乳腺癌患者的预后更差,但结局差异是由于年龄还是存在侵袭性临床特征仍存在争议。一项真实世界...
8. Laura Morsberger, Aparna Pallavajjala , Patty Long, et al.HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. Cancer Cell Int. 2022 Nov 15;22(1):350.
精准分层辅助内分泌治疗策略与规范随诊随访共同助力HR+/HER2-早期乳腺癌患者走向治愈。 乳腺癌是严重威胁女性健康的恶性肿瘤之一,发病率呈逐年递增趋势。对于早期乳腺癌,临床以治愈为主要目标。HR+/HER2-是乳腺癌中最常见的亚型,辅助内分泌治疗作为HR+/HER2-早期乳腺癌患者的标准治疗方案之一,显著改善了患者的治疗结局...
5. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer 6. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer 7. Modi S, ...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
Advanced Triple Negative Breast Cancer 肿瘤瞭望:SG和T-DXd均已获批用于mTNBC的二线治疗,尽管无头对头证据的比较,但基于既往注册研究数据和临床实践经验,您如何优化这两种ADC在mTNBC中的治疗顺序? Both SG and T-DXd have been approved for second-line treatment of mTNBC.Despite the lack of head-to-head com...
Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach tha
NSCLC, the well-known immunohistochemistry (IHC) scoring system ranging between 0 and 3+ (with IHC 0-1+ defined as HER2 negative, IHC 2+ as weak to moderate and IHC 3+ as strong when staining in 10% of tumour cells), remains the most frequently used method to detect HER2 overexpression...
(ratio < 2.0 with HER2 signal ≥ 4.0, but < 6.0; AC2013), use of an alternative chromosome 17 probe reassigned 212 (7.4% overall) patients to FISH-positive and 36 (1.3% overall) patients to FISH-negative, whereas 157 (5.5% overall) patients remained equivocal. Final HER2 positivity with...
et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in atients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a...